Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy


OZCAN M. F. , Dizdar O. , DINCER N., BALCI S., Guler G. , GOK B., ...Daha Fazla

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, cilt.31, sa.8, ss.1709-1715, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Konu: 8
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.urolonc.2012.06.014
  • Dergi Adı: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
  • Sayfa Sayıları: ss.1709-1715

Özet

Purpose: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance. Prognostic role of ERCC1 expression in the neoadjuvant setting in bladder cancer has not been reported before. We evaluated the prognostic role of ERCC1 expression in bladder cancer receiving platinum-based neoadjuvant chemotherapy.